Pembrolizumab + pemetrexed + platinum
Checked 2026-09-09
Metastatic non-squamous NSCLC without EGFR/ALK alteration, first line, any PD-L1
One cycle
every 21 days × 4 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Pembrolizumab Monoclonal antibody (anti-PD-1) | 200 mg | IV | D1 | or 400 mg every 6 weeks |
Pemetrexed Cytotoxic (antifolate) | 500 mg/m² | IV | D1 | |
Carboplatin AUC 5 or cisplatin 75 mg/m² Cytotoxic chemotherapy (platinum) | day 1, cycles 1-4 | IV | D1 |
Cycles
4 with platinum, then pembrolizumab + pemetrexed maintenance up to 35 cycles
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Folic acid, vitamin B12 and dexamethasone premedication for pemetrexed.
- Cisplatin makes the regimen highly emetogenic.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Pembrolizumab + carboplatin + paclitaxel
Metastatic squamous NSCLC, first line
every 21 days × 4
Nivolumab + ipilimumab + 2 cycles of platinum doublet
Metastatic NSCLC without EGFR/ALK alteration, first line
every 21 days
Osimertinib
EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)
every 28 days
Cisplatin + vinorelbine (adjuvant)
Completely resected stage IB (4 cm or larger) to IIIA NSCLC
every 28 days × 4
Chemoradiation then durvalumab (PACIFIC)
Unresectable stage III NSCLC without progression after platinum-based chemoradiation
every 28 days × 12
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Cisplatin + pemetrexed
Unresectable pleural mesothelioma (with or without bevacizumab); non-squamous NSCLC
every 21 days × 6